Fig. 2: Progression-free and overall survival for both sub-protocols.
From: Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
The PFS A and OS B are presented for both ALK (EAY131-F) and ROS1 (EAY131-G) sub-protocols.
